Establishing risk of human experimentation with drugs: lessons from TGN1412
- PMID: 17046471
- DOI: 10.1016/S0140-6736(06)69562-7
Establishing risk of human experimentation with drugs: lessons from TGN1412
Comment in
-
Lessons from TGN1412.Lancet. 2006 Nov 4;368(9547):1569-70; author reply 1570. doi: 10.1016/S0140-6736(06)69651-7. Lancet. 2006. PMID: 17084746 No abstract available.
-
Risk in drug trials.Lancet. 2006 Dec 23;368(9554):2205. doi: 10.1016/S0140-6736(06)69881-4. Lancet. 2006. PMID: 17189020 No abstract available.
-
Risk in drug trials.Lancet. 2006 Dec 23;368(9554):2205. doi: 10.1016/S0140-6736(06)69882-6. Lancet. 2006. PMID: 17189021 No abstract available.
-
Risk in drug trials.Lancet. 2006 Dec 23;368(9554):2205-6. doi: 10.1016/S0140-6736(06)69883-8. Lancet. 2006. PMID: 17189022 No abstract available.
-
TGN1412 and The Lancet's solicitation of reports of phase I trials.Lancet. 2006 Dec 23;368(9554):2206-7. doi: 10.1016/S0140-6736(06)69885-1. Lancet. 2006. PMID: 17189023 No abstract available.
-
Risk in drug trials.Lancet. 2006 Dec 23;368(9554):2206. doi: 10.1016/S0140-6736(06)69884-X. Lancet. 2006. PMID: 17189024 No abstract available.
Publication types
MeSH terms
Substances
Associated data
- Actions
- Actions
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical